McLaughlin Gerald W.
Known title: DirectorCIK: 0001495412
Associated companies
Transaction History
| ALLR | ▲ Buy | Grant | 45,000 | $0 | 1/28/2026 | View on chart |
| ALLR | ▲ Buy | Grant | 45,000 | $0 | 1/28/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Allarity Therapeutics expands lab capabilities and highlights DRP technology
Allarity reported progress on its Drug Response Predictor platform, noting its role in advancing the clinical development of Stenoparib. The company also announced that its in‑house laboratory now includes proteomics and cell‑line research capabilities. These updates are intended to strengthen the drug development program and support existing partnerships. The stock remains near the lower end of its 52‑week price range.
Allarity Therapeutics expands lab capabilities and highlights DRP technology. Allarity reported progress on its Drug Response Predictor platform, noting its role in advancing the clinical development of Stenoparib. The company also announced that its in‑house laboratory now includes proteomics and cell‑line research capabilities. These updates are intended to strengthen the drug development program and support existing partnerships. The stock remains near the lower end of its 52‑week price range.